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Background: BRCA2 mutation carriers are at increased risk for multiple cancers including pancreatic adenocarci-
noma (PAC). Our goal was to compare the effectiveness of different PAC screening strategies in BRCA2 mutation
carriers, from the standpoint of life expectancy.
Methods: A previously published Markov model of PAC was updated and extended to incorporate key aspects of
BRCA2mutation carrier status, including competing risks of breast- and ovarian-cancer speciﬁcmortality. BRCA2
mutation carriers were modeled and analyzed as the primary cohort for the analysis. Additional higher risk
BRCA2 cohorts that were stratiﬁed according to the number of ﬁrst-degree relatives (FDRs) with PAC
were also analyzed. For each cohort, one-time screening and annual screening were evaluated, with screening
starting at age 50 in both strategies. The primary outcome was net gain in life expectancy (LE) compared to no
screening. Sensitivity analysis was performed on key model parameters, including surgical mortality and MRI
test performance.
Findings:One-time screening at age 50 resulted in a LE gain of 3.9 days for the primary BRCA2 cohort, and a gain of
5.8 days for those with BRCA2 and one FDR. Annual screening resulted in LE loss of 12.9 days for the primary co-
hort and 1.3 days for BRCA2 carriers with 1 FDR, but resulted in 20.6 days gained for carriers with 2 FDRs and
260 days gained for those with 3 FDRs. For patients with ≥3 FDRs, annual screening starting at an earlier age
(i.e. 35–40) was optimal.
Interpretation: Among BRCA2 mutation carriers, aggressive screening regimens may be ineffective unless addi-
tional indicators of elevated risk (e.g., 2 or more FDRs) are present. More clinical studies are needed to conﬁrm
these ﬁndings.
Funding:American Cancer Society –New England Division – Ellison Foundation Research Scholar Grant (RSG-15-
129-01-CPHPS).
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
While the BRCA2 mutation is best known for its associated elevated
breast and ovarian cancer risk, it also conveys an increased risk of pan-
creatic adenocarcinoma (PAC) as the most common genetic alteration
found in familial pancreatic cancer. Consequently, some BRCA2 muta-
tion carriers are screened for PAC with imaging. To date, however, con-
sensus guidelines that deﬁne how screening should be implemented to
beneﬁtmutation carriers – i.e. the frequency and duration of screening–
are not available. In a recent statement of the International Cancer of the
Pancreas Screening (CAPS) Consortium, most members felt that BRCA2
mutation carriers with ≥1 affected ﬁrst-degree relative, or with two af-
fected relatives (whether or not ﬁrst degree), should be considered can-
didates for screening (Canto et al., 2013). However, agreement was not
reached on whether mutation carriers without a family history of PAC
should be screened.
The lack of consensus largely stems from the limited data available
to guide any given PAC screening strategy in BRCA2 mutation carriers.
To date, themajority of clinical trials that have been performed to deter-
mine the value of PAC screening in high-risk individuals have been
small single-arm trials (Canto et al., 2013; Langer et al., 2009; Verna
et al., 2010; Al-Sukhni et al., 2012; Ludwig et al., 2011), and none have
been speciﬁc to BRCA2 mutation carriers. Recently, we used a simula-
tion modeling approach to project potential life expectancy gains for
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individuals who underwent one-time MRI screening at age 50 and
found that gains are possible if a cohort's relative risk for PAC was sufﬁ-
ciently high (Canto et al., 2013). Our ﬁndings suggest that screening
once at age 50may be of beneﬁt (Pandharipande et al., 2015). However,
our study did not incorporate interval screening for patients who were
negative on their ﬁrst screening study or model patients with speciﬁc
genetic mutations such as BRCA2.
While some might advocate that the effectiveness of PAC screening
in BRCA2 mutation carriers should be evaluated with a clinical trial,
such an approach is not practical as a ﬁrst-line method for addressing
this issue, as the scale of the trial (including the number of subjects
and required follow-up duration) makes such an approach unfeasible.
In such scenarios, a simulation model can be used to gain greater in-
sights into potential beneﬁts of screening in BRCA2 mutation carriers,
and also provide data to inform the design of a clinical trial. Equally im-
portant, such a model can be probed to identify factors that are likely to
drive the success – and failure – of PAC screening efforts in this popula-
tion. In our current analysis, we substantiallymodiﬁed our previous PAC
model to address a population of BRCA2mutation carriers, and to allow
for an MRI screening regimen at regular intervals over many years,
reﬂecting common PAC screening practices in high-risk individuals.
Our purpose was to estimate the impact of PAC screening on life expec-
tancy in BRCA2 mutation carriers.
2. Methods
2.1. Overview of the Model
We previously developed a Markov model to simulate the natural
history of PAC in hypothetical populations with varied levels of PAC
risk. The model was calibrated to data from the National Cancer
Institute's Surveillance, Epidemiology, and End Results (SEER) cancer
registry and published literature (Howlader et al., 2013; Key, 2007;
Brugge et al., 2004; Tempero et al., 2010; Surveillance, Epidemiology,
and End Results (SEER), 2013; Laffan et al., 2008; Canto et al., 2012).
In each simulation, a hypothetical patient cohort begins in a “normal”
health state at age 20, and is followed until death or age 100. Patients can
progress to PAC via two separate pathways – solid and cystic –which ac-
count for 90% vs. 10% of PAC, respectively (Key, 2007; Brugge et al., 2004;
Tempero et al., 2010). PACs are further categorized into SEER historic
stages. Patients who develop PAC begin with pre-clinical or undetected
localized cancer and may progress to more advanced stages. Once
diagnosed, patients are subject to stage-dependent mortality rates de-
rived directly from SEER data (Howlader et al., 2013). Probabilities
governing transitions between health states were calibrated to data
from the SEER registry and published data, as previously described
(Pandharipande et al., 2015; Howlader et al., 2013; Key, 2007; Brugge
et al., 2004; Surveillance, Epidemiology, and End Results (SEER), 2013;
Laffan et al., 2008; Canto et al., 2012).
Screening regimens can be overlaid onto this natural history model,
potentially resulting in the earlier detection of PACs. Patients detected in
the localized PAC state are treated surgically. In the cystic pathway,
screening may also result in detection of precursor lesions (low-risk
and high-risk cysts, predominantly intraductal papillary mucinous neo-
plasms [IPMNs]) (Canto et al., 2012). High-risk cysts prompt surgery,
while low-risk cysts undergo annual surveillance for ten years; surgery
is prompted in instances of progression. Patients who survive surgical
resection of a high-risk cyst return to a baseline (i.e., “normal”) health
state, while those who survive surgery for PAC are subject to localized
PAC mortality based on SEER estimates (Howlader et al., 2013). While
a cure is possible for a subset of these patients, the majority die from
their cancer.
SEER data are representative of the U.S. population (Howlader et al.,
2013). In order to model subgroups within the population with varying
degrees of elevated PAC risk, the baseline risks of developing and dying
from PAC were scaled according to a relative risk factor (e.g., 10× the
general population), and model parameter estimates such as transition
probabilities governing PAC progression rates were recalibrated to re-
produce these higher targets. This approach allowed us to estimate
the effect of screening in cohorts with elevated PAC risk.
Full details of model structure and assumptions, parameter esti-
mates, calibration targets and process are available in the published ar-
ticle (Pandharipande et al., 2015). The current analysis included several
modiﬁcations and extensions to this model, as described below.
2.2. Model Incorporation of the BRCA2 Mutation
The current analysis necessitated two principal modiﬁcations to our
previously validated model. First, in the original model, competing risk
of death was determined by age- and gender-speciﬁc mortality rates
drawn from U.S. life tables for the total population (Arias and United
States Life Tables, 2008). However, BRCA2mutation carriers have an in-
creased risk of breast and ovarian cancers and thus a higher all-cause
mortality rate. To account for this, SEER data on age- and cancer-
speciﬁc relative survival (in the total population) and the age-speciﬁc
incidence of breast and ovarian cancers (in BRCA2 mutation carriers)
were used to adjust the all-cause mortality rates for BRCA2 mutation
carriers using a previously applied method (Antoniou et al., 2004; Lee
et al., 2008).
Second, the screening component of themodel was expanded to in-
corporate additional screening strategies. In the original model, all pa-
tients were evaluated with “one-time” screening at the age of 50.
Although formal guidelines are lacking, in clinical practice, patients at
high risk for PACmay be screened from ages 50–80, frequently between
an annual and triennial basis (Brand et al., 2007). For the current study,
we analyzed two screening strategies: one time screening at age 50, and
annual screening beginning at age 50 and continuing until age 80.
Table 1
Relative risk of PAC in BRCA2 cohorts, surgical mortality, and screening performance.
Parameter Value References
Relative risk of PAC
Primary cohorta 3.5 Canto et al. (2013) and The Breast
Cancer Linkage Consortium (1999))
# of FDRsb
1 4.5 Canto et al. (2013) and Grover and
Syngal (2010)
2 6.4 Canto et al. (2013) and Grover and
Syngal (2010)
≥3 32.0 Canto et al. (2013) and Grover and
Syngal (2010)
Surgical mortality rate
Surgical mortality 1%c Pellegrini et al. (1989), Crist et al.
(1987), Fernandez-del Castillo et al.
(2012), Finks et al. (2011), Winter et al.
(2006) and Reames et al. (2014)
Test performance
characteristics for MRI
screening strategy
Sensitivity 56% (5/9) Langer et al. (2009), Verna et al. (2010),
Al-Sukhni et al. (2012), Ludwig et al.
(2011), Canto et al. (2012) and Vasen
et al. (2011)
Speciﬁcity 97%
(739/760)
Langer et al. (2009), Verna et al. (2010),
Al-Sukhni et al. (2012), Ludwig et al.
(2011), Canto et al. (2012) and Vasen
et al. (2011)
a BRCA2 mutation carriers without a speciﬁc number of FDRs (i.e. “all-comers”).
b Relative risks for BRCA2 mutation carriers with affected FDRs.
c Range = 1–6%; 1% estimate weighted towards more favorable outcomes in screen-
detected patients; range from 0 to 10% tested in sensitivity analysis.
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2.3. Elevated Levels of PAC Risk and Additional Key Input Parameters
2.3.1. Risk of Pancreatic Adenocarcinoma (PAC) Compared to the General
Population
Estimates of PAC risk in study cohorts of interest were derived from
the literature and are included in Table 1. For the primary cohort, a hy-
pothetical cohort of “all-comer” BRCA2 mutation carriers – i.e. those
without a pre-speciﬁed number of FDRs – were assigned a relative
risk of 3.5× greater than that of the general population (Canto et al.,
2013; The Breast Cancer Linkage Consortium, 1999). For higher risk co-
horts of BRCA2mutation carriers with one, two, and three ormore FDRs
with a history of PAC, each group was assigned relative risks based on
the number of affected FDRs as reported in the literature, independent
of BRCA2 mutation carrier status. This simpliﬁed approach was neces-
sary because data regarding the risk of PAC in patients with both
BRCA2 mutations and various numbers of FDRs were not available.
Hence, estimates for the increased risk in BRCA2 carriers who also had
FDRs may have been low. They were as follows: 4.5× the general popu-
lation for patients with one affected FDR, 6.4× for patients with two af-
fected FDRs, and 32.0× for patients with three or more FDRs (Canto
et al., 2013; Grover and Syngal, 2010). All-cause mortality rates for
these patients still reﬂected the BRCA2-adjusted mortality rates.
2.3.2. MRI Test Performance
Data from six single-arm patient studies that utilized PAC screening
with ﬁrst-line MRI (including MR cholangiopancreatography, and with
concurrent or follow-up EUS in most cases with positive MRI results)
were used to compute the sensitivity and speciﬁcity of parameters
used in the model (overall sensitivity = 56%, overall speciﬁcity = 97%
(Table 1)) (Langer et al., 2009; Verna et al., 2010; Al-Sukhni et al.,
2012; Ludwig et al., 2011; Canto et al., 2012; Vasen et al., 2011). We
classiﬁed cases from these studies into true-positive, false-negative,
true-negative, and false-positive categories to derive these estimates
using uniform criteria, as previously described (Pandharipande et al.,
2015). We assumed independent results between screens.
We appliedMRI test performance characteristics in themodel as fol-
lows (Pandharipande et al., 2015). In the solid pathway, we assumed
precursor lesions (pancreatic intraepithelial neoplasias) could not be
detected. Therefore, in the solid pathway, false-negative cases were
those in which patients localized PAC were misclassiﬁed as healthy,
and false-positive cases were those in which healthy patients were
misclassiﬁed as having PAC. In the cystic pathway, detection of low-
risk and high-risk cysts (precursor lesions) was possible in our model.
The proportion of patients with cysts who ultimately underwent sur-
gery in a large screening trial was used as a proxy to determine the pro-
portion of patients with high-risk (vs. low-risk) cysts (Pandharipande
et al., 2015; Canto et al., 2012). In the cystic pathway, false-negative
cases were those in which a low-risk cyst, high-risk cyst, or localized
PAC was missed on screening, while false-positive cases were those in
which a low-risk cyst was misclassiﬁed as high-risk (or as PAC). We
did not incorporate the possibility of misdiagnosing a healthy patient
as having a cyst or a cyst-derived PAC. The same test performance char-
acteristics were used to determine the probability of each type of error
in classiﬁcation.
2.3.3. Surgical Mortality
Patients with high-risk cystic lesions or localized PAC underwent
surgery and were subject to surgical mortality risk. The surgical mortal-
ity rate may be impacted by factors such as patient age, performance
status, and institution (Pellegrini et al., 1989; Crist et al., 1987;
Fernandez-del Castillo et al., 2012; Finks et al., 2011; Winter et al.,
2006; Reames et al., 2014). In our current model, we used a surgical
mortality rate of 1%, a rate on the lower end of the published rates rang-
ing from 1 to 6%, because asymptomatic patients tend to be healthier
than symptomatic patients diagnosed with cancer, and are therefore
more likely to survive surgery (Table 1) (Pellegrini et al., 1989; Crist
et al., 1987; Fernandez-del Castillo et al., 2012; Finks et al., 2011;Winter
et al., 2006; Reames et al., 2014).
2.4. Sensitivity Analyses
In sensitivity analysis, we evaluated additional screening strategies
(inwhich the starting age of screening and screening intervalswere fur-
ther varied) to determine effects on model results. In addition, we per-
formed extensive one-way deterministic analyses to evaluate the
stability of our results to varied estimates of MRI sensitivity, MRI speci-
ﬁcity, and surgical mortality.
2.5. Role of the Funding Source
The model development and analysis, and interpretation of the
model results – as well as manuscript writing, preparation, and the de-
cision to submit the manuscript –were at the sole discretion of the au-
thors and not the Sponsor.
3. Results
Changes in life expectancy associated with the two screening strate-
gies (one-time and annual screening) across all study cohorts are in-
cluded in Table 2. One-time screening at age 50 for the primary cohort
resulted in a LE gain of 3.9 days. One-time screening in cohorts with af-
fected FDRs had greater returns: 5.8 days of life gained for BRCA2 car-
riers with one FDR, 9.1 days with two FDRs, and 31.5 days with three
or more FDRs. Annual screening from ages 50–80 resulted in a LE loss
of 12.9 days for the primary cohort as well as a loss of 1.3 days for
BRCA2 carriers with one affected FDR. However, annual screening re-
sulted in LE gains of 20.6 days with two FDRs and 260.0 days with
three or more FDRs.
Sensitivity analysis shows changes in LE gainswhen varying starting
age for screening, over a range of 30–70, for each strategy. For the pri-
mary cohort, LE gains persisted for starting ages above 32 and peaked
when applying a strategy of one-time screening at age 49 (Fig. 1). For
cohorts with affected FDRs, the results are as follows:With one affected
FDR, LE gains persisted for all starting ages and peaked with one-time
screening at age 48 (Fig. 2a). With two FDRs, LE gains peaked with an-
nual screening starting at age 52 (Fig. 2b). With three or more FDRs,
LE gains peaked with annual screening starting at age 37 (Fig. 2c).
Results were also sensitive to changes in MRI sensitivity. For the pri-
mary cohort, the values tested ranged from25 to 100% (Fig. 3a, 50–100%
graphed). The threshold valuewhere one-time screeningwas no longer
effective (i.e. resulted in LE loss) was when sensitivity was less than
27.7%. The threshold valuewhere one-time screeningwas no longer su-
perior to annual screeningwaswhen sensitivity was greater than 94.0%.
For cohorts with affected FDRs, thresholds at which point one-time
screening at age 50 was no longer effective were: 23.2%, 18.8%, and
15.8% for one, two, and three or more FDRs, respectively. Thresholds
where one-time screening was no longer superior to annual screening
Table 2
Net life expectancy (days) gained by screening for PAC in individuals with BRCA2
mutations.
BRCA2 mutation carriers
Strategy No
screening
One-time screening:
age 50
Annual screening:
ages 50–80
Primary cohorta – 3.9b −12.9
# of FDRs
1 – 5.8b −1.3
2 – 9.1 20.6b
≥3 – 31.5 260.0b
a BRCA2 mutation carriers without a speciﬁc number of FDRs (i.e. “all-comers”).
b The numbersbolded represent the “optimal” strategy for the cohort as determined by
most net gain in life expectancy (days gained).
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Fig. 1. Sensitivity analysis for starting age for screening in primary cohort BRCA2 carriers. Starting age was varied over a range of 30–70, and for each strategy, life expectancy past age 20
was measured.
Fig. 2. Sensitivity analysis for starting age for screening in BRCA2 carrierswith one (A), two (B), and three ormore (C) ﬁrst degree relatives. Starting agewas varied over a range of 30–70,
and for each strategy, life expectancy past age 20 was measured.
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were: 67.2%, 43.6%, and 16.4% for one, two, and three or more FDRs,
respectively.
Results were also sensitive to changes in MRI speciﬁcity. For the pri-
mary cohort, the values tested ranged from50 to 100% (Fig. 3b, 90–100%
graphed). The threshold valuewhere one-time screeningwas no longer
effective was when speciﬁcity was less than 93.6%. The threshold
value where one-time screening was no longer superior to annual
screening was when speciﬁcity was greater than 98.2%. For the co-
horts with affected FDRs, thresholds at which point one-time screen-
ing at age 50 was no longer effective were: 91.8%, 88.6%, and 53.0%
for one, two, and three or more FDRs, respectively. Thresholds
where one-time screening was no longer superior to annual screen-
ing were: 97.6%, 96.6%, and 78.2% for one, two, and three or more
FDRs, respectively.
Results were also sensitive to changes in surgical mortality. For
the primary cohort, the values tested ranged from 0 to 10% (Fig. 3c,
0.0–2.5% graphed). One-time screening was no longer effective was
when surgical mortality rates were greater than 2.3%. The thresh-
old value for when one-time screening was no longer superior to
annual screening was when surgical mortality was below 0.6%.
For the cohorts with affected FDRs, thresholds at which point
one-time screening at age 50 was no longer effective were: 3.0%
and 4.2% for one and two FDRs, respectively, and the threshold
was above 10% for three or more FDRs. Thresholds where one-
time screening was no longer superior to annual screening were:
0.8%, 1.2%, and 8.1% for one, two and three or more FDRs,
respectively.
3.1. Screening Interval
A sensitivity analysis on screening interval showed that for the pri-
mary cohort, screening less frequently than every 3.9 years led to a
gain in LE. Similarly, screening BRCA2 mutation carriers with one FDR
less often than 1.4 years led to a net LE gain. For the higher risk groups
with either two FDRs or three or more FDRs, screening less frequently
than annually resulted in diminished LE gain.
3.2. Two-way Sensitivity Analysis
We also performed a two-way deterministic sensitivity analysis of
surgical mortality rate and MRI speciﬁcity. The interaction of the two
parameters is presented in Fig. 4. Generally, the combination of lower
surgicalmortality rates andhigherMRI speciﬁcity values leads to annual
screening being superior.
4. Discussion
We found that one-time screening of BRCA2 mutation carriers can
increase life expectancy. Despite heightened PAC risk in this cohort,
more aggressive screening at regular intervals may result in diminished
life expectancy. This ﬁnding can be attributed to a phenomenon that is
increasingly recognized in cancer screening initiatives: an increased
number of false-positive results, which can occurwhen healthy patients
are screened repeatedly, can lead to more harm than beneﬁt. This is
Fig. 3. Sensitivity analysis for MRI sensitivity (A), MRI speciﬁcity (B), and surgical mortality (C). Sensitivity (Sens) was varied over a range of 25–100% (50–100% graphed), speciﬁcity
(Spec) over a range of 50–100% (90–100% graphed), and surgical mortality (SMort) over a range of 0–10% (0.0–2.5% graphed). For each strategy, net days gained by screening for PAC
in individuals with BRCA2 mutations were measured.
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particularly important in the setting of PAC, given the relatively high
morbidity andmortality risks of pancreatic surgery.Whenwe evaluated
subsets of BRCA2 mutation carriers with varying numbers of FDRs, we
found that only those with multiple FDRs (two or more) would beneﬁt
from annual screening. Conversely, high-risk BRCA2 mutation carriers
with three or more FDRs might beneﬁt from an even earlier starting
age for screening. In this setting, PAC risk is high enough that the bene-
ﬁts of increased screening frequency outweigh the harms. In addition to
the burden of false-positive results, the beneﬁt of screening is signiﬁ-
cantly limited, even in high risk individuals, by the poor efﬁcacy of
PAC treatment, an area of medicine in dire need of improvement. Five
year survival for patients with PAC diagnosed at an early stage and
whoundergo successful resectionwith clear surgicalmargins (R0 resec-
tion) remains low at b20% (Wagner et al., 2004). Evenwithin this select
group, over 80% of PAC tumors recurwithmetastatic disease, asmany of
these patients already have micrometastases at diagnosis that are not
detectable by current imagingmodalities (Garrido-Laguna and Hidalgo,
2015). Promising new adjuvant and neoadjuvant therapeutic regimens
may improve survival for early stage PAC patients(Neoptolemos et al.,
2010; Oettle et al., 2007) and could signiﬁcantly alter the calculus for
screening beneﬁt in the near future.
Previous smaller studies have found that screening in high-risk co-
horts may be able to detect preinvasive pancreatic lesions amenable to
interventions such as surgery (Verna et al., 2010; Canto et al., 2012), al-
though the relatively low number of positive ﬁndings in screening stud-
ies and a lack of evidence that early identiﬁcation will improve cancer
survival or outcomes has tempered enthusiasm (Langer et al., 2009). A
2007 consensus conference proposed that screening for PAC be restrict-
ed to individuals with greater than ten-fold increased risk (Brand et al.,
2007). Additionally, the National Comprehensive Cancer Network
guidelines do not currently recommend pancreatic screening for pa-
tients with BRCA mutations. The lack of guidelines and data to inform
clinical practice was the primary motivation for our analysis.
A strength of our analysis was that our model was calibrated to NCI
SEER data, making many aspects of the natural history generalizable to
the US population. An additional strength was that our model incorpo-
rated the risks of death from the key cancers associatedwith BRCA2mu-
tation, breast and ovarian, into all-cause mortality rates, thereby
providing more accurate estimates for life expectancies within this
unique cohort of patients.
Our study had limitations. Potential interactions between BRCA2
mutation carrier status and the number of FDRs afﬂicted with PAC
were not available in the literature and therefore simplifying assump-
tions regarding their independenceweremade. Although ourmodel in-
puts were based on the published literature, in some cases limited data
were available, creating uncertainty; to address this, extensive sensitiv-
ity analyses were performed to assess the robustness of the ﬁndings. In
addition, MRI screening performance continues to evolve and novel im-
aging technologies are a focus of much research; improvements to a
screening modality in which both sensitivity and speciﬁcity increase
could affect our conclusions. Moreover, we did not address EUS as a
ﬁrst-line imaging strategy for PAC screening; while our sensitivity anal-
ysis results provide insight into potential beneﬁts (or losses) associated
with a spectrum of possible test performance characteristics, future
studies that compare MRI and EUS, and which further examine their
complementary capabilities for lesion detection, are warranted. Future
clinical studies are needed to conﬁrm our estimates of the impact of
screening on PAC survival in BRCA2 cohorts.
Although our study was geared towards guiding PAC screening in
BRCA2mutation carriers, our ﬁndings suggest that screeningmay be ef-
fective in other patients or cohorts with genetic syndromes such as Fa-
milial Atypical Multiple Mole Melanoma Syndrome and Peutz–Jeghers
Syndrome, which are less prevalent but are associated with extremely
high risks of PAC; the optimal screening regimen, however, would
need to be analyzed in separate analyses.
In conclusion, we found that in BRCA2 mutation carriers, one-time
MRI-based PAC screening at age 50 can be effective and increase life ex-
pectancy, albeit with marginal beneﬁt. More aggressive screening at
regular intervals may be harmful, as the number of false positives accu-
mulates with repeat examinations, and the burden of the resulting sur-
gical interventions may outweigh the beneﬁt of cancer mortality
reduction. If the risk of PAC is very high, such as in patients with multi-
ple ﬁrst degree relativeswith PAC, annualMRI screening (starting at age
50 for two FDRs and age 35–40 for three ormore FDRs)may be optimal.
Future clinical studies are needed to conﬁrm our ﬁndings.
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